Literature DB >> 24375963

The effect of various zinc binding groups on inhibition of histone deacetylases 1-11.

Andreas S Madsen1, Helle M E Kristensen, Gyrithe Lanz, Christian A Olsen.   

Abstract

Histone deacetylases (HDACs) have the ability to cleave the acetyl groups of ε-N-acetylated lysine residues in a variety of proteins. Given that human cells contain thousands of different acetylated lysine residues, HDACS may regulate a wide variety of processes including some implicated in conditions such as cancer and neurodegenerative disorders. Herein we report the synthesis and in vitro biochemical profiling of a series of compounds, including known inhibitors as well as novel chemotypes, that incorporate putative new zinc binding domains. By evaluating the compound collection against all 11 recombinant human HDACs, we found that the trifluoromethyl ketone functionality provides potent inhibition of all four subclasses of the Zn(2+) -dependent HDACs. Potent inhibition was observed with two different scaffolds, demonstrating the efficiency of the trifluoromethyl ketone moiety as a zinc binding motif. Interestingly, we also identified silanediol as a zinc binding group with potential for future development of non-hydroxamate class I and class IIb HDAC inhibitors.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  epigenetics; histone deacetylases; inhibitors; silanediols; trifluoromethyl ketones; zinc

Mesh:

Substances:

Year:  2013        PMID: 24375963     DOI: 10.1002/cmdc.201300433

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  13 in total

Review 1.  Developing drugs targeting transition metal homeostasis.

Authors:  Claire M Weekley; Chuan He
Journal:  Curr Opin Chem Biol       Date:  2016-12-29       Impact factor: 8.822

Review 2.  Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.

Authors:  Shikha Kumari; Angelica V Carmona; Amit K Tiwari; Paul C Trippier
Journal:  J Med Chem       Date:  2020-08-04       Impact factor: 7.446

Review 3.  Histone Deacetylase Inhibitors: A Prospect in Drug Discovery.

Authors:  Rakesh Yadav; Pooja Mishra; Divya Yadav
Journal:  Turk J Pharm Sci       Date:  2018-12-31

Review 4.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

5.  Exploring the influence of the protein environment on metal-binding pharmacophores.

Authors:  David P Martin; Patrick G Blachly; J Andrew McCammon; Seth M Cohen
Journal:  J Med Chem       Date:  2014-08-19       Impact factor: 7.446

Review 6.  Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

Authors:  Madhusoodanan Mottamal; Shilong Zheng; Tien L Huang; Guangdi Wang
Journal:  Molecules       Date:  2015-03-02       Impact factor: 4.411

7.  Microwave-assisted synthesis and antitumor evaluation of a new series of thiazolylcoumarin derivatives.

Authors:  Moustafa T Gabr; Nadia S El-Gohary; Eman R El-Bendary; Mohamed M El-Kerdawy; Nanting Ni
Journal:  EXCLI J       Date:  2017-08-30       Impact factor: 4.068

8.  Novel glyoxalase-I inhibitors possessing a "zinc-binding feature" as potential anticancer agents.

Authors:  Qosay A Al-Balas; Mohammad A Hassan; Nizar A Al-Shar'i; Nizar M Mhaidat; Ammar M Almaaytah; Fatima M Al-Mahasneh; Israa H Isawi
Journal:  Drug Des Devel Ther       Date:  2016-08-17       Impact factor: 4.162

9.  Diversity-oriented synthesis of analogues of the novel macrocyclic peptide FR-225497 through late stage functionalization.

Authors:  Jyotiprasad Mukherjee; Suman Sil; Shital Kumar Chattopadhyay
Journal:  Beilstein J Org Chem       Date:  2015-12-08       Impact factor: 2.883

10.  Assessment of the Allelochemical Activity and Biochemical Profile of Different Phenotypes of Picocyanobacteria from the Genus Synechococcus.

Authors:  Zofia Konarzewska; Sylwia Śliwińska-Wilczewska; Aldo Barreiro Felpeto; Vitor Vasconcelos; Adam Latała
Journal:  Mar Drugs       Date:  2020-03-27       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.